WXIBF (WuXi Biologics (Cayman)) Short-Term Debt: $124 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.60
GF Value $5.17
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Short-Term Debt?

WuXi Biologics (Cayman) WXIBF 97 Short-Term Debt is $124 Mil as of Dec. 2025. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.17 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WuXi Biologics (Cayman)'s Short-Term Debt for the quarter that ended in Dec. 2025 was $124 Mil.

WuXi Biologics (Cayman)'s quarterly Short-Term Debt increased from Dec. 2024 ($334 Mil) to Jun. 2025 ($355 Mil) but then declined from Jun. 2025 ($355 Mil) to Dec. 2025 ($124 Mil).

WuXi Biologics (Cayman)'s annual Short-Term Debt increased from Dec. 2023 ($81 Mil) to Dec. 2024 ($334 Mil) but then declined from Dec. 2024 ($334 Mil) to Dec. 2025 ($124 Mil).

WuXi Biologics (Cayman) Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

WuXi Biologics (Cayman) Short-Term Debt Related Terms

WuXi Biologics (Cayman) Short-Term Debt Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Short-Term Debt Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 333.14 189.54 80.72 334.49 124.02

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.72 123.04 334.49 354.79 124.02
WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $124 Mil mean?
WuXi Biologics (Cayman) (WXIBF) has a Short-Term Debt of $124 Mil as of Dec. 2025.
Is WuXi Biologics (Cayman)'s Short-Term Debt too high?
WuXi Biologics (Cayman)'s current Short-Term Debt is $124 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Short-Term Debt compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Short-Term Debt of $124 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. WuXi Biologics (Cayman)'s current Short-Term Debt is $124 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.17, compared to a current price of $4.60 — trading 11% below its estimated fair value. The current Short-Term Debt is $124 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Short-Term Debt is $124 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.60 is trading 11% below its estimated GF Value™ of $5.17. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Short-Term Debt: $124 Mil
  • GF Value™: $5.17 vs. price of $4.60 (11% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$5.17
GF Value